{"id":"buprenorphine-injectable-product","safety":{"commonSideEffects":[{"rate":null,"effect":"Headache"},{"rate":null,"effect":"Nausea"},{"rate":null,"effect":"Dizziness"},{"rate":null,"effect":"Constipation"},{"rate":null,"effect":"Injection site reactions"},{"rate":null,"effect":"Respiratory depression"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Buprenorphine acts as a partial agonist at the mu-opioid receptor, producing analgesia and euphoria at lower levels than full opioid agonists due to its ceiling effect on respiratory depression. This pharmacological profile makes it suitable for both pain management and opioid use disorder treatment, with reduced potential for abuse and overdose compared to full mu-opioid agonists.","oneSentence":"Buprenorphine is a partial mu-opioid receptor agonist that binds with high affinity to reduce pain and opioid cravings while carrying lower overdose risk than full agonists.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T00:55:31.763Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Moderate to severe acute and chronic pain"},{"name":"Opioid use disorder maintenance treatment"}]},"trialDetails":[{"nctId":"NCT04677114","phase":"PHASE2","title":"Integrated Outpatient Treatment of Opioid Use Disorder and Severe Injection Related Infections","status":"COMPLETED","sponsor":"Laura Fanucchi","startDate":"2021-03-16","conditions":"Drug Use, Opioid-use Disorder","enrollment":71},{"nctId":"NCT06576843","phase":"PHASE2","title":"INDV-6001 Multiple-Dose Pharmacokinetic Study","status":"COMPLETED","sponsor":"Indivior Inc.","startDate":"2024-09-17","conditions":"Moderate to Severe Opioid Use Disorder","enrollment":123},{"nctId":"NCT03911466","phase":"","title":"Medication Treatment for Opioid Use Disorder in Expectant Mothers: Conceptual Model Assessments Sub-study","status":"COMPLETED","sponsor":"T. John Winhusen, PhD","startDate":"2020-07-21","conditions":"Opioid-Related Disorders, Drug Addiction, Pregnancy Related","enrollment":97},{"nctId":"NCT03911739","phase":"","title":"Medication Treatment for Opioid Use Disorder in Expectant Mothers: Infant Neurodevelopmental Outcomes Sub-study","status":"COMPLETED","sponsor":"T. John Winhusen, PhD","startDate":"2021-06-14","conditions":"Opioid-Related Disorders, Drug Addiction, Pregnancy Related","enrollment":71},{"nctId":"NCT07469501","phase":"PHASE4","title":"Comparing Outpatient Treatment Retention Among Individuals Using Fentanyl Randomized to Low-dose and Direct-to-inject Buprenorphine Initiation","status":"NOT_YET_RECRUITING","sponsor":"University of California, San Francisco","startDate":"2026-06","conditions":"Opioid Use Disorder, Fentanyl","enrollment":50},{"nctId":"NCT06726200","phase":"EARLY_PHASE1","title":"A Clinical Trial Comparing Buprenorphine Formulations for High Potency Synthetic Opioid Use","status":"RECRUITING","sponsor":"Rachel R. Luba","startDate":"2026-08","conditions":"Opioid Use Disorder","enrollment":60},{"nctId":"NCT07439549","phase":"PHASE4","title":"Symptom-Inhibited Naloxone Induction (SINI) for Buprenorphine Initiation: A Feasibility Trial","status":"NOT_YET_RECRUITING","sponsor":"Pouya Azar","startDate":"2026-02-18","conditions":"Opioid Use Disorder","enrollment":12},{"nctId":"NCT05991622","phase":"PHASE2","title":"Combined Injectable Treatment for HIV and OUD","status":"WITHDRAWN","sponsor":"Rhode Island Hospital","startDate":"2022-04-01","conditions":"Human Immunodeficiency Virus, Opioid Use Disorder","enrollment":""},{"nctId":"NCT06854029","phase":"PHASE4","title":"NOTRE: Optimizing Long-Acting Pre-Exposure Prophylaxis and Medications for Opioid Use Disorder Interventions in Carceral Settings","status":"NOT_YET_RECRUITING","sponsor":"Duke University","startDate":"2026-06","conditions":"HIV Infections, Opioid Use Disorder, Incarceration; Lens","enrollment":300},{"nctId":"NCT04245423","phase":"NA","title":"The Whole Health Study: Collaborative Care for OUD and Mental Health Conditions","status":"ACTIVE_NOT_RECRUITING","sponsor":"University of Pennsylvania","startDate":"2020-12-15","conditions":"Opioid-use Disorder, Mental Health Conditions","enrollment":567},{"nctId":"NCT04276259","phase":"PHASE4","title":"Rapid Antidepressant Improvement Secondary to Excitatory Brain Responses","status":"COMPLETED","sponsor":"Marta Peciña, MD PhD","startDate":"2020-10-19","conditions":"Major Depressive Disorder, Depression","enrollment":120},{"nctId":"NCT04995029","phase":"PHASE4","title":"Buprenorphine Extended-Release Subcutaneous Injection (RBP-6000) in High-risk Users","status":"COMPLETED","sponsor":"Indivior Inc.","startDate":"2021-10-26","conditions":"Moderate to Severe Opioid-use Disorder","enrollment":785},{"nctId":"NCT04408313","phase":"PHASE2, PHASE3","title":"Extended Release Naltrexone Versus Extended Release Buprenorphine With Individuals Leaving Jail","status":"ACTIVE_NOT_RECRUITING","sponsor":"Friends Research Institute, Inc.","startDate":"2020-10-28","conditions":"Opioid-use Disorder","enrollment":240},{"nctId":"NCT04375033","phase":"PHASE4","title":"A Study Comparing Oral Buprenorphine and Injectable Buprenorphine for the Treatment of Opioid Use Disorder","status":"RECRUITING","sponsor":"VA Office of Research and Development","startDate":"2020-11-03","conditions":"Opioid Use Disorder","enrollment":952},{"nctId":"NCT06023459","phase":"PHASE3","title":"Extended-release Buprenorphine Compared to Sublingual Buprenorphine in Rural Settings (RXR)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Yih-Ing Hser","startDate":"2024-10-14","conditions":"Opioid-Related Disorders, Substance-Related Disorders, Narcotic-Related Disorders","enrollment":144},{"nctId":"NCT07296770","phase":"PHASE3","title":"An Artificial Intelligence Driven Approach to Optimize Patient Selection for a Transitional Pain Service","status":"NOT_YET_RECRUITING","sponsor":"University of California, San Francisco","startDate":"2026-05-01","conditions":"Postsurgical Pain Management, Postsurgical Pain, Chronic, Opioid Use After Surgery","enrollment":126},{"nctId":"NCT04464980","phase":"PHASE2","title":"Optimizing Retention, Duration and Discontinuation Strategies for Opioid Use Disorder Pharmacotherapy (RDD)","status":"ACTIVE_NOT_RECRUITING","sponsor":"NYU Langone Health","startDate":"2021-06-08","conditions":"Opioid Use Disorder (OUD)","enrollment":1516},{"nctId":"NCT05262270","phase":"PHASE2","title":"Extended-Release Naltrexone and Monthly Extended-Release Buprenorphine for Cocaine Use Disorder (CURB-2)","status":"COMPLETED","sponsor":"University of Texas Southwestern Medical Center","startDate":"2023-04-18","conditions":"Cocaine Use Disorder","enrollment":427},{"nctId":"NCT04600414","phase":"NA","title":"Collaborating to Heal Addiction and Mental Health in Primary Care","status":"COMPLETED","sponsor":"University of Washington","startDate":"2020-11-16","conditions":"Opioid-use Disorder, Mental Health Disorder","enrollment":254},{"nctId":"NCT06051890","phase":"PHASE4","title":"Assessing Optimal XRB Initiation Points in Jail","status":"RECRUITING","sponsor":"NYU Langone Health","startDate":"2025-06-02","conditions":"Opioid Use Disorder","enrollment":200},{"nctId":"NCT04454411","phase":"PHASE2","title":"Brain Mechanisms of Pharmacotherapy in Opioid Use Disorder","status":"TERMINATED","sponsor":"University of Pennsylvania","startDate":"2022-08-01","conditions":"Opioid Dependence","enrollment":3},{"nctId":"NCT05528848","phase":"PHASE1","title":"Multi-System Analysis of Opioid Receptor Binding","status":"RECRUITING","sponsor":"University of Pennsylvania","startDate":"2022-09-20","conditions":"Healthy, Opioid Use Disorder","enrollment":60},{"nctId":"NCT03918850","phase":"PHASE3","title":"Medication Treatment for Opioid Use Disorder in Expectant Mothers","status":"COMPLETED","sponsor":"T. John Winhusen, PhD","startDate":"2020-07-21","conditions":"Opioid-Related Disorders, Drug Addiction, Pregnancy Related","enrollment":140},{"nctId":"NCT04219540","phase":"PHASE4","title":"Long-acting Buprenorphine vs. Naltrexone Opioid Treatments in CJS-involved Adults","status":"COMPLETED","sponsor":"NYU Langone Health","startDate":"2021-01-07","conditions":"Opioid-use Disorder","enrollment":675},{"nctId":"NCT04180020","phase":"NA","title":"Coordinating Opioid Use Treatment Through Medical Management With Infection Treatment (Project COMMIT)","status":"COMPLETED","sponsor":"Yale University","startDate":"2020-08-18","conditions":"Opioid-use Disorder","enrollment":171},{"nctId":"NCT03993392","phase":"PHASE4","title":"SUBLOCADE Rapid Initiation Study","status":"COMPLETED","sponsor":"Indivior Inc.","startDate":"2019-08-29","conditions":"Opioid-use Disorder","enrollment":26},{"nctId":"NCT05283304","phase":"PHASE2","title":"Monthly Injectable BUP for MA Use Disorder (MURB) Trial","status":"TERMINATED","sponsor":"Madhukar H. Trivedi, MD","startDate":"2023-03-24","conditions":"Methamphetamine-dependence","enrollment":18},{"nctId":"NCT06880718","phase":"PHASE4","title":"Injectable Buprenorphine in Prison: a Preference Trial","status":"NOT_YET_RECRUITING","sponsor":"Lifespan","startDate":"2025-06","conditions":"Opioid Use Disorder, Incarceration, Medications for Opioid Use Disorder","enrollment":60},{"nctId":"NCT03221309","phase":"","title":"Hepatitis C Treatment to Prevent HIV, Initiate Opioid Substitution Therapy, and Reduce Risky Behavior","status":"ACTIVE_NOT_RECRUITING","sponsor":"University of Maryland, Baltimore","startDate":"2017-05-01","conditions":"HCV, Buprenorphine, PreP","enrollment":198},{"nctId":"NCT03747341","phase":"PHASE1","title":"Buprenorphine-Fentanyl Interaction Study","status":"COMPLETED","sponsor":"Indivior Inc.","startDate":"2018-03-22","conditions":"Healthy, Opioid Use","enrollment":22},{"nctId":"NCT04225598","phase":"PHASE2","title":"Emergency Department-Initiated Buprenorphine Validation Network Trial","status":"COMPLETED","sponsor":"Yale University","startDate":"2020-07-08","conditions":"Opioid-use Disorder","enrollment":2000},{"nctId":"NCT04480554","phase":"PHASE2","title":"Anti-retroviral Therapy, Medications for Opioid Use Disorder, Opioids and HIV Infection - Study 1","status":"RECRUITING","sponsor":"University of Pennsylvania","startDate":"2023-01-30","conditions":"Opioid-use Disorder, HIV-1-infection, Immune Activation","enrollment":225},{"nctId":"NCT04575324","phase":"NA","title":"Project STAMINA (Syringe Service Telemedicine Access for Medication-assisted Intervention Through NAvigation)","status":"COMPLETED","sponsor":"Chestnut Health Systems","startDate":"2020-08-24","conditions":"Opioid-use Disorder","enrollment":275},{"nctId":"NCT06354465","phase":"","title":"Injectable Extended-Release Buprenorphine (XR-B) in a Correctional Setting: Qualitative Interviews","status":"RECRUITING","sponsor":"Lifespan","startDate":"2023-07-01","conditions":"Opioid Use Disorder, Criminal Justice, Treatment Adherence and Compliance","enrollment":25},{"nctId":"NCT05481112","phase":"PHASE4","title":"Assessing Optimal XR-Buprenorphine Initiation Points in Jail","status":"WITHDRAWN","sponsor":"NYU Langone Health","startDate":"2023-11-01","conditions":"Opioid Use Disorder","enrollment":""},{"nctId":"NCT05164549","phase":"PHASE3","title":"Extended-release Pharmacotherapy for Opioid Use Disorder","status":"COMPLETED","sponsor":"King's College London","startDate":"2019-08-06","conditions":"Opiate Substitution Treatment","enrollment":342},{"nctId":"NCT03976258","phase":"","title":"Effect of Heroin Use on Immune Activation and Cardiovascular Risk in HIV","status":"COMPLETED","sponsor":"MetroHealth Medical Center","startDate":"2017-07-14","conditions":"HIV Infection, Opioid-use Disorder, Cardiovascular Diseases","enrollment":190},{"nctId":"NCT04254081","phase":"PHASE4","title":"Addition of Buprenorphine to Paracervical Block for Pain Control During Osmotic Dilator Insertion","status":"COMPLETED","sponsor":"University of California, San Diego","startDate":"2020-05-28","conditions":"Procedural Pain, Buprenorphine, Adjuvants, Anesthesia","enrollment":57},{"nctId":"NCT03647774","phase":"PHASE4","title":"Long Acting Naltrexone for Opioid Addiction: Focus on Sustained Abstinence and Recovery","status":"COMPLETED","sponsor":"Lars Tanum","startDate":"2018-08-01","conditions":"Opioid-use Disorder","enrollment":317},{"nctId":"NCT04815590","phase":"","title":"Extended-release Injectable Buprenorphine for Individuals at High Risk of Overdose","status":"UNKNOWN","sponsor":"BC Centre on Substance Use","startDate":"2022-10-17","conditions":"Opioid-Use Disorder, Opioid Overdose","enrollment":40},{"nctId":"NCT05594121","phase":"PHASE4","title":"Monthly Versus Daily Buprenorphine Formulations for Treatment of Opiate Use Disorder","status":"UNKNOWN","sponsor":"Royal Victoria Hospital, Canada","startDate":"2022-12","conditions":"Moderate to Severe Opioid Use Disorder","enrollment":90},{"nctId":"NCT03933865","phase":"PHASE1","title":"Acute Pain Management in Patients on Opioid Replacement Therapy","status":"TERMINATED","sponsor":"University of California, San Francisco","startDate":"2018-10-31","conditions":"Opioid-use Disorder, Pain, Acute","enrollment":1},{"nctId":"NCT05549492","phase":"PHASE1","title":"Transversus Abdominis Plane Block With or Without Buprenorphine After Inguinal Hernia Surgery","status":"COMPLETED","sponsor":"Egymedicalpedia","startDate":"2021-01-01","conditions":"Inguinal Hernia, Pain, Postoperative","enrollment":64},{"nctId":"NCT04139213","phase":"PHASE2, PHASE3","title":"Medication Maintenance Therapy in Community Pharmacy Settings","status":"UNKNOWN","sponsor":"Lifespan","startDate":"2019-07-25","conditions":"Opioid-use Disorder","enrollment":250},{"nctId":"NCT03744663","phase":"PHASE2","title":"Long Acting Buprenorphine Injection Compared to Sublingual Buprenorphine/Naloxone Films","status":"WITHDRAWN","sponsor":"Wake Forest University Health Sciences","startDate":"2022-06","conditions":"Opioid Use","enrollment":""},{"nctId":"NCT03604159","phase":"PHASE4","title":"XRB vs. SLB in Jail and at Re-entry: Pilot, Proof of Concept","status":"COMPLETED","sponsor":"NYU Langone Health","startDate":"2019-06-24","conditions":"Opioid Dependence","enrollment":52},{"nctId":"NCT01843023","phase":"PHASE4","title":"Extended Release Naltrexone for Opioid-Dependent Youth","status":"COMPLETED","sponsor":"Friends Research Institute, Inc.","startDate":"2013-06","conditions":"Drug Dependence","enrollment":288},{"nctId":"NCT00270257","phase":"PHASE3","title":"Drug Treatment Combined With Drug and Risk Reduction Counseling to Prevent of HIV Infection and Death Among Injection Drug Users","status":"TERMINATED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2008-05","conditions":"HIV Infections, Opioid-Related Disorders","enrollment":1251},{"nctId":"NCT01402492","phase":"PHASE2, PHASE3","title":"Cocaine Use Reduction With Buprenorphine","status":"COMPLETED","sponsor":"University of California, Los Angeles","startDate":"2011-09","conditions":"Cocaine Dependence","enrollment":302},{"nctId":"NCT05090761","phase":"NA","title":"Serratus Anterior Plane Block With and Without Adjuvants in Video-assisted Thoracoscopy","status":"UNKNOWN","sponsor":"Wayne State University","startDate":"2021-10-12","conditions":"Post Operative Pain, Acute","enrollment":120},{"nctId":"NCT02946073","phase":"PHASE3","title":"Buprenorphine (CAM2038) in Subjects With a Recent History of Moderate to Severe Chronic Low Back Pain","status":"COMPLETED","sponsor":"Braeburn Pharmaceuticals","startDate":"2016-09","conditions":"Chronic Lower Back Pain, Chronic Pain","enrollment":1053},{"nctId":"NCT05003765","phase":"NA","title":"Are Superficial Parasternal Intercostal Plane (SPIP) Blocks With Bupivacaine and With or Without Adjuvants Helpful for Post-operative Pain After Coronary Artery Bypass Grafting?","status":"UNKNOWN","sponsor":"Wayne State University","startDate":"2020-08-06","conditions":"Post-operative Pain Management","enrollment":200},{"nctId":"NCT01999946","phase":"PHASE4","title":"Extended-Release Naltrexone Opioid Treatment at Jail Re-Entry","status":"COMPLETED","sponsor":"NYU Langone Health","startDate":"2014-06-27","conditions":"Heroin Dependence, Opioid-Related Disorders","enrollment":217},{"nctId":"NCT02710526","phase":"PHASE2","title":"Phase II Pharmacokinetics Study of CAM2038","status":"COMPLETED","sponsor":"Braeburn Pharmaceuticals","startDate":"2015-02","conditions":"Opioid Use Disorder, Chronic Pain","enrollment":66},{"nctId":"NCT02583243","phase":"","title":"Project BEST: Buprenorphine Entry Into Substance Abuse Treatment","status":"COMPLETED","sponsor":"Yale University","startDate":"2005-05","conditions":"Opioid-related Disorders, HIV Infections, Hepatitis C, Chronic","enrollment":209},{"nctId":"NCT02294253","phase":"PHASE2, PHASE3","title":"Buprenorphine/Naloxone Stabilization and Induction Onto Injection Naltrexone","status":"COMPLETED","sponsor":"New York State Psychiatric Institute","startDate":"2014-09","conditions":"Opioid Dependence","enrollment":30},{"nctId":"NCT02651584","phase":"PHASE3","title":"Clinical Trial of CAM2038, Long-acting Subcutaneous Buprenorphine Injections for Treatment of Patients With Opioid Dependence","status":"COMPLETED","sponsor":"Braeburn Pharmaceuticals","startDate":"2015-12","conditions":"Opioid Use Disorders","enrollment":428},{"nctId":"NCT03766893","phase":"EARLY_PHASE1","title":"Medication Maintenance Therapy in Community Pharmacy Settings","status":"COMPLETED","sponsor":"Lifespan","startDate":"2018-09-01","conditions":"Opioid-use Disorder","enrollment":11},{"nctId":"NCT02537574","phase":"PHASE3","title":"Naltrexone for Use in Conjunction With Buprenorphine in Adults With Opioid Use Disorder Prior to First Dose of VIVITROL® (Naltrexone for Extended-Release Injectable Suspension)","status":"COMPLETED","sponsor":"Alkermes, Inc.","startDate":"2015-08","conditions":"Opioid Use Disorder","enrollment":380},{"nctId":"NCT01717963","phase":"PHASE3","title":"Naltrexone vs Buprenorphine-Naloxone for Opioid Dependence in Norway","status":"COMPLETED","sponsor":"University of Oslo","startDate":"2012-10","conditions":"Opioid Dependence","enrollment":166},{"nctId":"NCT01708707","phase":"PHASE2","title":"Comparison of Buprenorphine to Morphine in Treatment of Neonatal Abstinence Syndrome (NAS)","status":"COMPLETED","sponsor":"Pediatrix","startDate":"2012-12","conditions":"Neonatal Abstinence Syndrome, Neonatal Withdrawal Syndrome","enrollment":29},{"nctId":"NCT01377610","phase":"PHASE1","title":"Improved Strategies for Outpatient Opioid Detoxification","status":"COMPLETED","sponsor":"New York State Psychiatric Institute","startDate":"2011-06","conditions":"Opioid Dependence","enrollment":150},{"nctId":"NCT02044094","phase":"PHASE2","title":"Multiple Dose Study of Blockade of Opioid Effects by Injections of Buprenorphine in Participants With Opioid Disorder","status":"COMPLETED","sponsor":"Indivior Inc.","startDate":"2013-11","conditions":"Opioid Use Disorder","enrollment":39},{"nctId":"NCT01761110","phase":"NA","title":"Pilot Test of a Community-based Buprenorphine Treatment Intervention","status":"COMPLETED","sponsor":"Albert Einstein College of Medicine","startDate":"2012-12","conditions":"Opioid Dependence, Injection Drug Use","enrollment":77},{"nctId":"NCT02510014","phase":"PHASE3","title":"Safety and Tolerability Study of Depot Buprenorphine in Treatment Seeking Subjects With Opioid Use Disorder","status":"COMPLETED","sponsor":"Indivior Inc.","startDate":"2015-07-27","conditions":"Opioid Use Disorder, Opioid-related Disorders","enrollment":775},{"nctId":"NCT02357901","phase":"PHASE3","title":"Treatment Seeking Participants With Opioid Use Disorders Assessing Tolerability of Depot Injections of Buprenorphine","status":"COMPLETED","sponsor":"Indivior Inc.","startDate":"2015-01-28","conditions":"Opioid Dependence, Opioid Related Disorders","enrollment":665},{"nctId":"NCT02372591","phase":"PHASE1","title":"Study of the Treatment of Experimental Pain in Buprenorphine Maintained Persons With Chronic Musculoskeletal Pain","status":"COMPLETED","sponsor":"Johns Hopkins University","startDate":"2015-08","conditions":"Opioid-Related Disorders, Chronic Pain","enrollment":14},{"nctId":"NCT01642030","phase":"PHASE1","title":"Study of the Treatment of Experimental Pain in Opioid Dependent Persons on Methadone or Buprenorphine Maintenance","status":"COMPLETED","sponsor":"Johns Hopkins University","startDate":"2013-08","conditions":"Opioid Dependence, Pain, Addiction","enrollment":132},{"nctId":"NCT00134875","phase":"NA","title":"Assessing Abuse Potential of Parenteral Buprenorphine/Naloxone in Non-Dependent Opioid Abusers","status":"TERMINATED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2000-12","conditions":"Opioid-Related Disorders","enrollment":9},{"nctId":"NCT03002961","phase":"PHASE1","title":"Single Ascending Dose Study of RBP-6000","status":"COMPLETED","sponsor":"Indivior Inc.","startDate":"2012-07","conditions":"Opioid Use Disorder","enrollment":48},{"nctId":"NCT01690546","phase":"PHASE2","title":"Low Dose Naltrexone-buprenorphine Transfer to Vivitrol Injection in Opioid Dependence","status":"COMPLETED","sponsor":"Paolo Mannelli","startDate":"2012-09","conditions":"Opiate Dependence","enrollment":38},{"nctId":"NCT00987961","phase":"PHASE3","title":"Linking Hospitalized Injection Drug Users to Buprenorphine","status":"COMPLETED","sponsor":"Butler Hospital","startDate":"2009-09","conditions":"Opiate Dependence","enrollment":147},{"nctId":"NCT01723527","phase":"PHASE1","title":"Diversion to Treatment for Injection Drug Users Arrested for Possession of Heroin","status":"COMPLETED","sponsor":"Johns Hopkins University","startDate":"2012-12","conditions":"Cocaine-Related Disorders, HIV, Heroin Dependence","enrollment":1}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Sublocade®; prev. RBP-60000"],"phase":"phase_3","status":"active","brandName":"Buprenorphine Injectable Product","genericName":"Buprenorphine Injectable Product","companyName":"King's College London","companyId":"king-s-college-london","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Buprenorphine Injectable Product is a small molecule that acts as a mu opioid receptor agonist, classified as an agonist. It is used to treat conditions such as Opioid Use Disorder, Neonatal Abstinence Syndrome, and Neonatal Withdrawal Syndrome, among others.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}